Lilly also participates in the TrumpRx direct-to-consumer program at approximately $350 per month
They were originally created to help treat type 2 diabetes, but their efficacy on weight loss has pivoted them to be used more broadly for obesity treatment
A 2025 study of 228,000 individuals with obesity, Type 2 diabetes, or alcohol use disorder, semaglutide and liraglutide use was associated with a 36% and 28% lower risk, respectively, of alcohol-related hospitalizations (such as intoxication and withdrawal symptoms) compared to patients who weren't prescribed GLP-1 medications (Lhteenvuo et al., 2025)
This is supported by the template, which aligns with the growing evidence base
14 In the stomach, GLP-1 agonists slow gastric emptying
This prevents introducing contaminants that could degrade the peptide or cause injection site reactions